The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study
第一作者机构:[7]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
推荐引用方式(GB/T 7714):
Niu Shuhuai.The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA:
Niu, Shuhuai.(2023).The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA:
Niu, Shuhuai."The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)